Skip to main content
Clinical Trials/NCT04810806
NCT04810806
Terminated
Not Applicable

Immediate Versus Delayed Coronary Angiography in Patients With Non-ST-Segment Acute Coronary Syndrome With Acute Decompensated Heart Failure

Chonnam National University Hospital1 site in 1 country316 target enrollmentApril 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Chonnam National University Hospital
Enrollment
316
Locations
1
Primary Endpoint
Cumulative incidence rate of all-cause death, non-fatal myocardial infarction or recurrent ischemia
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The investigators hypothesized that immediate coronary angiography (CAG) within 2 hours after admission can reduce mortality compared to delayed CAG after stabilization of acute decompensated heart failure (ADHF) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) complicated by ADHF. Patients with NSTE-ACS complicated by ADHF will be randomized to immediate CAG (coronary angiography < 2 hours after randomization) or delayed CAG after stablization group by 1:1 fashion. This study is a prospective, non-blinded, randomized trial.

Detailed Description

Study objective In this study, investigators aim to compare early coronary angiography (CAG \< 2 hours after randomization) and delayed CAG after stabilization of acute decompensated heart failure (ADHF) in patients with acute non-ST-elevation acute coronary syndrome (NSTE-ACS) complicated by ADHF. This study is a prospective, non-blinded, randomized trial. Study background An ADHF is frequently encountered in patients with NSTE-ACS. Although its incidence has been decreased during the decades, it is still high up to 8-12% at initial presentation of NSTE-ACS. Patients with NSTE-ACS complicated by ADHF is also known to be associated with worse in-hospital and long-term clinical outcomes than those without heart failure (HF). Because revascularization could reduce mortality in these patients, it should be done in all patients with NSTE-ACS with ADHF. Current guidelines recommend immediate CAG within 2 hours after admission in patients with NSTE-ACS complicated by ADHF. However, it is difficult to decide the timing of coronary angiography in these high risk patients. Notably, the most of randomized trials about the timing of coronary angiography in NSTE-ACS excluded these high risk patients, therefore there is lack of evidence for immediate coronary angiography within 2 hours after admission in patients with NSTE-ACS complicated by ADHF. Investigators will compare immediate CAG within 2 hours after admission and delayed CAG after stabilization of ADHF in patients with NSTE-ACS complicated by ADHF by randomized controlled trial. Study hypothesis Immediate CAG within 2 hours after admission can reduce mortality compared to delayed CAG after stabilization of ADHF in patients with NSTE-ACS complicated by ADHF.

Registry
clinicaltrials.gov
Start Date
April 1, 2021
End Date
March 1, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Min Chul Kim

Associate Professor

Chonnam National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Age more than 18 years old
  • Pulmonary congestion or edema on chest X-ray
  • The definition of NSTE-ACS
  • Among patients with typical angina, dyspnea or chest discomfort without definite non-cardiac causes, at least 1 presentations of angina that suggest a NSTE-ACS:
  • Rest angina, which is usually more than 20 minutes in duration
  • New onset angina that markedly limits physical activity
  • Increasing angina that is more frequent, longer in duration, or occurs with less exertion than previous angina
  • A 12-lead electrocardiogram should have no ST-segment elevation. Cardiac troponin may elevate (non-ST-segment elevation myocardial infarction) or not elevate (unstable angina pectoris).

Exclusion Criteria

  • Cardiogenic shock\* 2) Heart failure of other causes rather than NSTE-ACS 3) Terminal malignancy 4) Life expentancy \< 1 year 5) Pregnancy or lactation
  • \* The definition of cardiogenic shock All these criteria should be met
  • Systolic blood pressure \< 90 mmHg for 30 minutes, or needing inotropics or vasopressor to maintain systolic blood pressure \> or = 90 mmHg
  • Pulmonary congestion on chest X-ray or increased left ventricular filling pressure by cardiac catheterization
  • At least one criteria of organ dysfunction - mental obtundation, clammy ski, ogliuria, renal dysfunction, increased level of blood lactate

Outcomes

Primary Outcomes

Cumulative incidence rate of all-cause death, non-fatal myocardial infarction or recurrent ischemia

Time Frame: Up to 12 months

Cumulative incidence rate of all-cause death, non-fatal myocardial infarction or recurrent ischemia

Secondary Outcomes

  • In-hospital mortality(Up to 12 months)
  • Rate of procedural complications during coronary angiography or percutaneous coronary intervention(Up to 12 months)
  • Rate of recurrent ischemia(Up to 12 months)
  • Usage rate of non-invasive positive pressure ventilation(Up to 12 months)
  • Cumulative incidence rate of cardiogenic shock(Up to 12 months)
  • Cumulative incidence rate of major bleeding (BARC classification 3-5)(Up to 12 months)
  • Cumulative incidence rate of non-fatal myocardial infarction(Up to 12 months)
  • Peak level of troponin-I(Up to 12 months)
  • Cumulative incidence rate of rehospitalization due to heart failure(Up to 12 months)
  • Rate of all-cause death, non-fatal myocardial infarction or recurrent ischemia(Up to 12 months)
  • In-hospital cardiac mortality(Up to 12 months)
  • Usage rate of mechanical ventilator(Up to 12 months)
  • Usage rate of renal replacement therapy(Up to 12 months)
  • Duration of initial hospitalization(Up to 12 months)
  • Cumulative incidence rate of stroke(Up to 12 months)
  • Cumulative incidence rate of stent thrombosis(Up to 12 months)
  • Cumulative incidence rate of recurrent ischemia(Up to 12 months)
  • Rate of Non-fatal myocardial infarction(Up to 12 months)
  • Rate of major bleeding(Up to 12 months)
  • Cumulative incidence rate of all-cause death, non-fatal myocardial infarction or recurrent ischemia(Up to 1 month)
  • Cumulative incidence rate of all unplanned revascularization(Up to 12 months)
  • Rate of stroke(Up to 12 months)
  • Usage rate of mechanical circulatory support(Up to 12 months)
  • Rate of acute kidney injury(Up to 12 months)
  • Rate of stent thrombosis(Up to 12 months)
  • Cumulative incidence rate of all-cause death(Up to 12 months)
  • Cumulative incidence rate of cardiac death(Up to 12 months)

Study Sites (1)

Loading locations...

Similar Trials